German messenger RNA specialist BioNTech SE has signed agreements with Pfizer Inc. and Shanghai Fosun Pharmaceutical Group Co. Ltd. for rights to its investigational COVID-19 vaccine. The mRNA vaccine candidate, BNT162, is expected to enter clinical trials in late April 2020.
Mainz-based BioNTech is building on an existing relationship with Pfizer: the two companies established an R&D collaboration for mRNA flu vaccines in 2018. (Also see "Interview: BioNTech And Pfizer...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?